Wave Life Sciences Stock: An Fairly Valued RNA Opportunity (NASDAQ:WVE)
· seekingalpha.com
Wave Life Sciences (WVE) stock analysis: low valuation (2.45x cash, no debt) vs. RNA therapy competition; key upside tied to WVE-N531 results. See more here.
Lately, Wave has not had the best time; the stock is down around 25% over the past
Max is an independent equity research analyst with a primary focus on biotec...